Financial Releases

Common stock expected to begin trading tomorrow under new Nasdaq ticker symbol “LFCR” Lifecore global headquarters relocated to Chaska, MN Launches new investor relations website: ir.lifecore.com CHASKA, Minn., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc.

CHASKA, Minn. , Nov. 10, 2022 (GLOBE NEWSWIRE) -- Landec Corporation (Nasdaq: LNDC) (“Lifecore” or the “Company”), a diversified health and wellness company with two operating businesses, Lifecore Biomedical, Inc. (“Lifecore”) and Curation Foods, Inc. (“Curation Foods”), – today announced that Jim

CHASKA, Minn. , Nov. 01, 2022 (GLOBE NEWSWIRE) -- Landec Corporation (Nasdaq: LNDC) (“Lifecore” or the “Company”) today announced that it expects to effect its previously announced corporate name change to Lifecore Biomedical, Inc. and to cause its common stock to begin trading on Nasdaq under the

Lifecore segment revenues increased 8.0% to $23.7 million in fiscal 2023 first quarter versus the prior year period Lifecore segment EBITDA increased 8.1% to $2.5 million in fiscal 2023 first quarter versus the prior year period Reiterates fiscal 2023 full year guidance for Lifecore Corporate

SANTA MARIA, Calif. and MINNEAPOLIS , Sept. 28, 2022 (GLOBE NEWSWIRE) -- Landec Corporation (Nasdaq: LNDC) (“Landec” or the “Company”), a diversified health and wellness company focused on its growing Lifecore Biomedical (“Lifecore”) business – a fully integrated contract development and

SANTA MARIA, Calif. and MINNEAPOLIS , Sept. 21, 2022 (GLOBE NEWSWIRE) -- Landec Corporation (Nasdaq: LNDC) (“Landec” or the “Company”), a diversified health and wellness company focused on its growing Lifecore Biomedical (“Lifecore”) business – a fully integrated contract development and

SANTA MARIA, Calif. and MINNEAPOLIS , Sept. 09, 2022 (GLOBE NEWSWIRE) -- Landec Corp. (NASDAQ: LNDC) (the “Company”) announced today that it received a notice (“Notice”) on September 2, 2022 from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) stating that the Company is

Recently announced intent to rename and rebrand to Lifecore Biomedical, along with leadership and Board changes Lifecore segment revenues increased 6.9% to $27.6 million in fiscal fourth quarter, and increased 11.5% to $109.3 million for the full fiscal year 2022, as compared to the respective

Landec expected to rename and rebrand to Lifecore Biomedical and update Nasdaq ticker symbol Names new CEO Announces future changes to its Board of Directors SANTA MARIA, Calif. and MINNEAPOLIS, Minn. , Aug. 10, 2022 (GLOBE NEWSWIRE) -- Landec Corporation (Nasdaq: LNDC) (“Landec” or the “Company”),

SANTA MARIA, Calif. , July 27, 2022 (GLOBE NEWSWIRE) -- Landec Corporation (Nasdaq: LNDC) (“Landec” or the “Company”), a diversified health and wellness company focused on its growing Lifecore Biomedical (“Lifecore”) business – a fully integrated contract development and manufacturing organization